In addition, actionable mutations in genes including BRAF and DNA repair genes have been identified in around half of patients with pancreatic ductal adenocarcinoma using real-time whole-exome sequencing, with second-line targeted therapy showing early promise in selected patients [89]. Here, BRAF is linked to pancreatic ductal adenocarcinoma.